phosphorylcholine has been researched along with Cardiovascular Diseases in 27 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Natural antibodies specific for phosphorylcholine (anti-PC) have been implicated as protective factors in atherosclerosis." | 7.75 | Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. ( Berglund, G; Dahlbom, I; de Faire, U; Frostegård, J; Grönlund, H; Hedblad, B; Sjöberg, BG; Su, J; Wikström, M, 2009) |
| "Atherosclerosis is an inflammatory condition characterised by an abundance of activated immunocompetent cells in plaques which cause cardiovascular disease (CVD) when they rupture." | 6.46 | Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease. ( Frostegård, J, 2010) |
| "Phosphorylcholine (PC) is an important pro-inflammatory damage-associated molecular pattern." | 5.62 | Identification of IgG1 isotype phosphorylcholine antibodies for the treatment of inflammatory cardiovascular diseases. ( Bergman, A; Dahlbom, I; de Jong, RCM; de Vries, MR; Ewing, MM; Frostegård, J; Jukema, JW; Karabina, SAP; Karper, JC; Kuiper, J; MacArthur, MR; Mitchell, JR; Ninio, E; Nordzell, M; Peters, EAB; Pettersson, K; Quax, PHA; Sexton, D, 2021) |
| "Natural antibodies specific for phosphorylcholine (anti-PC) have been implicated as protective factors in atherosclerosis." | 3.75 | Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men. ( Berglund, G; Dahlbom, I; de Faire, U; Frostegård, J; Grönlund, H; Hedblad, B; Sjöberg, BG; Su, J; Wikström, M, 2009) |
| "Hyperhomocysteinemia, a proposed risk factor for cardiovascular disease, is also observed in other common disorders." | 3.72 | Homocysteine-betaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency. ( Castro, C; Chen, Z; Garrow, T; Genest, J; Laryea, MD; Lussier-Cacan, S; Mar, MH; Rozen, R; Schwahn, BC; Wendel, U; Zeisel, SH, 2003) |
| "Atherosclerosis is the main cause of CVD in the general population, and in SLE, increased atherosclerosis, especially the prevalence of atherosclerotic plaques, has been demonstrated." | 3.01 | Systemic lupus erythematosus and cardiovascular disease. ( Frostegård, J, 2023) |
| "Atherosclerosis is an inflammatory condition characterised by an abundance of activated immunocompetent cells in plaques which cause cardiovascular disease (CVD) when they rupture." | 2.46 | Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease. ( Frostegård, J, 2010) |
| "Atherosclerosis is a chronic inflammatory disease characterized by the presence of activated immune-competent cells in the lesions, producing mainly proinflammatory cytokines." | 2.45 | Natural antibodies against phosphorylcholine in cardiovascular disease. ( de Faire, U; Frostegård, J, 2009) |
| "Phosphorylcholine (PC) is an important pro-inflammatory damage-associated molecular pattern." | 1.62 | Identification of IgG1 isotype phosphorylcholine antibodies for the treatment of inflammatory cardiovascular diseases. ( Bergman, A; Dahlbom, I; de Jong, RCM; de Vries, MR; Ewing, MM; Frostegård, J; Jukema, JW; Karabina, SAP; Karper, JC; Kuiper, J; MacArthur, MR; Mitchell, JR; Ninio, E; Nordzell, M; Peters, EAB; Pettersson, K; Quax, PHA; Sexton, D, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (33.33) | 29.6817 |
| 2010's | 12 (44.44) | 24.3611 |
| 2020's | 6 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Frostegård, J | 13 |
| Kim, YH | 1 |
| Her, AY | 1 |
| Rha, SW | 1 |
| Choi, BG | 1 |
| Choi, SY | 1 |
| Byun, JK | 1 |
| Park, Y | 1 |
| Kang, DO | 1 |
| Jang, WY | 1 |
| Kim, W | 1 |
| Choi, WG | 1 |
| Kang, TS | 1 |
| Ahn, J | 1 |
| Park, SH | 1 |
| Park, JY | 1 |
| Lee, MH | 1 |
| Choi, CU | 1 |
| Park, CG | 1 |
| Seo, HS | 1 |
| Samal, SK | 1 |
| Qureshi, AR | 2 |
| Rahman, M | 1 |
| Stenvinkel, P | 2 |
| Liu, J | 1 |
| Wang, J | 1 |
| Xue, YF | 1 |
| Chen, TT | 1 |
| Huang, DN | 1 |
| Wang, YX | 1 |
| Ren, KF | 1 |
| Wang, YB | 1 |
| Fu, GS | 1 |
| Ji, J | 1 |
| de Vries, MR | 1 |
| Ewing, MM | 1 |
| de Jong, RCM | 1 |
| MacArthur, MR | 1 |
| Karper, JC | 1 |
| Peters, EAB | 1 |
| Nordzell, M | 1 |
| Karabina, SAP | 1 |
| Sexton, D | 1 |
| Dahlbom, I | 3 |
| Bergman, A | 1 |
| Mitchell, JR | 1 |
| Kuiper, J | 1 |
| Ninio, E | 2 |
| Jukema, JW | 1 |
| Pettersson, K | 1 |
| Quax, PHA | 1 |
| Ajeganova, S | 1 |
| Andersson, MLE | 1 |
| Hafström, I | 1 |
| Guasch-Ferré, M | 1 |
| Hu, FB | 1 |
| Ruiz-Canela, M | 1 |
| Bulló, M | 1 |
| Toledo, E | 1 |
| Wang, DD | 1 |
| Corella, D | 1 |
| Gómez-Gracia, E | 1 |
| Fiol, M | 1 |
| Estruch, R | 1 |
| Lapetra, J | 1 |
| Fitó, M | 1 |
| Arós, F | 1 |
| Serra-Majem, L | 1 |
| Ros, E | 1 |
| Dennis, C | 1 |
| Liang, L | 1 |
| Clish, CB | 1 |
| Martínez-González, MA | 1 |
| Salas-Salvadó, J | 1 |
| Kankaanpää, J | 1 |
| Sämpi, M | 1 |
| Bloigu, R | 1 |
| Wang, C | 1 |
| Akhi, R | 1 |
| Kesäniemi, YA | 1 |
| Remes, AM | 1 |
| Ukkola, O | 1 |
| Hörkkö, S | 1 |
| Ge, D | 1 |
| Yue, HW | 1 |
| Liu, HH | 1 |
| Zhao, J | 1 |
| Agrawal, A | 1 |
| Gang, TB | 1 |
| Rusiñol, AE | 1 |
| Gigante, B | 1 |
| Leander, K | 1 |
| Vikström, M | 1 |
| Baldassarre, D | 1 |
| Veglia, F | 1 |
| Strawbridge, RJ | 1 |
| McLeod, O | 1 |
| Gertow, K | 1 |
| Sennblad, B | 1 |
| Shah, S | 1 |
| Zabaneh, D | 1 |
| Humphries, SE | 1 |
| Kauhanen, J | 1 |
| Rauramaa, R | 1 |
| Smit, AJ | 1 |
| Mannarino, E | 1 |
| Giral, P | 1 |
| Tremoli, E | 1 |
| Hamsten, A | 1 |
| de Faire, U | 5 |
| Montaño-Machado, V | 1 |
| Chevallier, P | 1 |
| Mantovani, D | 1 |
| Pauthe, E | 1 |
| Su, J | 3 |
| Hua, X | 3 |
| Concha, H | 1 |
| Svenungsson, E | 1 |
| Cederholm, A | 1 |
| Sjöberg, BG | 1 |
| Grönlund, H | 2 |
| Wikström, M | 2 |
| Hedblad, B | 1 |
| Berglund, G | 1 |
| Carrero, JJ | 1 |
| Heimbürger, O | 1 |
| Bárány, P | 1 |
| Lindholm, B | 1 |
| Frostegård, A | 1 |
| Halldin, M | 1 |
| Hellenius, ML | 1 |
| Rahman, I | 1 |
| Atout, R | 1 |
| Pedersen, NL | 1 |
| Bennet, AM | 1 |
| Magnusson, PK | 1 |
| Grönwall, C | 1 |
| Akhter, E | 1 |
| Oh, C | 1 |
| Burlingame, RW | 1 |
| Petri, M | 1 |
| Silverman, GJ | 1 |
| Algarra, M | 1 |
| Gomes, D | 1 |
| Esteves da Silva, JC | 1 |
| Schwahn, BC | 1 |
| Chen, Z | 1 |
| Laryea, MD | 1 |
| Wendel, U | 1 |
| Lussier-Cacan, S | 1 |
| Genest, J | 1 |
| Mar, MH | 1 |
| Zeisel, SH | 1 |
| Castro, C | 1 |
| Garrow, T | 1 |
| Rozen, R | 1 |
| Pepys, MB | 1 |
| Hirschfield, GM | 1 |
| Tennent, GA | 1 |
| Gallimore, JR | 1 |
| Kahan, MC | 1 |
| Bellotti, V | 1 |
| Hawkins, PN | 1 |
| Myers, RM | 1 |
| Smith, MD | 1 |
| Polara, A | 1 |
| Cobb, AJ | 1 |
| Ley, SV | 1 |
| Aquilina, JA | 1 |
| Robinson, CV | 1 |
| Sharif, I | 1 |
| Gray, GA | 1 |
| Sabin, CA | 1 |
| Jenvey, MC | 1 |
| Kolstoe, SE | 1 |
| Thompson, D | 1 |
| Wood, SP | 1 |
| Heinecke, JW | 1 |
| Kishi, H | 1 |
| Kawamichi, H | 1 |
| Kajiya, K | 1 |
| Kobayashi, S | 1 |
| Abizaid, A | 1 |
| Popma, JJ | 1 |
| Tanajura, LF | 1 |
| Hattori, K | 1 |
| Solberg, B | 1 |
| Larracas, C | 1 |
| Feres, F | 1 |
| Costa, Jde R | 1 |
| Schwartz, LB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Multi-Center, Non-Randomized, Single-Arm Trial to Evaluate the Safety and Feasibility of the TriMaxx Coronary Stent in de Novo Coronary Artery Lesions.[NCT00596661] | Phase 1 | 100 participants (Actual) | Interventional | 2004-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for phosphorylcholine and Cardiovascular Diseases
| Article | Year |
|---|---|
Systemic lupus erythematosus and cardiovascular disease.
Topics: Antibodies, Antiphospholipid; Atherosclerosis; Cardiovascular Diseases; Humans; Inflammation; Lupus | 2023 |
Emerging roles of sphingosylphosphorylcholine in modulating cardiovascular functions and diseases.
Topics: Animals; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Endothelial Cells; Humans; | 2018 |
Recognition functions of pentameric C-reactive protein in cardiovascular disease.
Topics: Animals; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Complement Activation; Gene E | 2014 |
Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease.
Topics: Animals; Atherosclerosis; Autoantibodies; Cardiovascular Diseases; Humans; Lipoproteins, LDL; Models | 2010 |
Natural antibodies against phosphorylcholine in cardiovascular disease.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Humans; Immunoglobulin M; Lipoproteins, LDL; Lupu | 2009 |
Current analytical strategies for C-reactive protein quantification in blood.
Topics: Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Ethanolamines; High-Throughput Screening As | 2013 |
[Involvement of Fyn tyrosine kinase and membrane rafts in the signal transduction in Ca2+-sensitization of vascular smooth muscle contraction].
Topics: Animals; Calcium; Cardiovascular Diseases; Cholesterol; Humans; Intracellular Signaling Peptides and | 2007 |
2 trials available for phosphorylcholine and Cardiovascular Diseases
| Article | Year |
|---|---|
Different subclasses and isotypes of antibodies against phosphorylcholine in haemodialysis patients: association with mortality.
Topics: Aged; Antibodies, Antiphospholipid; C-Reactive Protein; Cardiovascular Diseases; Disease-Free Surviv | 2020 |
Plasma Metabolites From Choline Pathway and Risk of Cardiovascular Disease in the PREDIMED (Prevention With Mediterranean Diet) Study.
Topics: Aged; Aged, 80 and over; Betaine; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Chi-Squ | 2017 |
18 other studies available for phosphorylcholine and Cardiovascular Diseases
| Article | Year |
|---|---|
Antibodies against phosphorylcholine and protection against atherosclerosis, cardiovascular disease and chronic inflammation.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Humans; Immunoglobulin G; Immunoglobulin M; Infla | 2022 |
Three-year major clinical outcomes of phosphorylcholine polymer- vs biolinx polymer-zotarolimus-eluting stents: A propensity score matching study.
Topics: Aged; Cardiovascular Diseases; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous | 2019 |
Biodegradable phosphorylcholine copolymer for cardiovascular stent coating.
Topics: Animals; Cardiovascular Diseases; Cells, Cultured; Coated Materials, Biocompatible; Molecular Struct | 2020 |
Identification of IgG1 isotype phosphorylcholine antibodies for the treatment of inflammatory cardiovascular diseases.
Topics: Animals; Anti-Inflammatory Agents; Antibodies, Monoclonal; Atherosclerosis; Cardiovascular Diseases; | 2021 |
Higher levels of anti-phosphorylcholine autoantibodies in early rheumatoid arthritis indicate lower risk of incident cardiovascular events.
Topics: Aged; Arthritis, Rheumatoid; Atherosclerosis; Autoantibodies; Cardiovascular Diseases; Female; Human | 2021 |
IgA antibodies to phosphocholine associate with long-term cardiovascular disease risk.
Topics: Biomarkers; Cardiovascular Diseases; Female; Finland; Humans; Immunodominant Epitopes; Immunoglobuli | 2018 |
Low levels of IgM antibodies against phosphorylcholine are associated with fast carotid intima media thickness progression and cardiovascular risk in men.
Topics: Age Factors; Aged; Anthropometry; Antibodies, Antiphospholipid; Antibody Specificity; Autoantigens; | 2014 |
On the potential for fibronectin/phosphorylcholine coatings on PTFE substrates to jointly modulate endothelial cell adhesion and hemocompatibility properties.
Topics: Cardiovascular Diseases; Cell Adhesion; Coated Materials, Biocompatible; Endothelial Cells; Fibronec | 2015 |
Natural antibodies against phosphorylcholine as potential protective factors in SLE.
Topics: Adult; Autoantibodies; Binding, Competitive; Cardiovascular Diseases; Cross Reactions; Endothelium, | 2008 |
Low levels of IgM antibodies against phosphorylcholine-A potential risk marker for ischemic stroke in men.
Topics: Aged; Atherosclerosis; Brain Ischemia; Cardiovascular Diseases; Cholesterol; Cohort Studies; Female; | 2009 |
Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis.
Topics: Aged; Cardiovascular Diseases; Female; Humans; Immunoglobulin M; Interleukin-6; Kidney Failure, Chro | 2009 |
Low levels of IgM antibodies to phosphorylcholine predict cardiovascular disease in 60-year old men: effects on uptake of oxidized LDL in macrophages as a potential mechanism.
Topics: Age Factors; Biomarkers; Cardiovascular Diseases; Cell Line; Female; Follow-Up Studies; Humans; Immu | 2010 |
Genetic and environmental regulation of inflammatory CVD biomarkers Lp-PLA2 and IgM anti-PC.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Biomarkers; Cardiovascular Diseases; Diseases | 2011 |
IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE.
Topics: Adult; Aged; Antibodies, Anti-Idiotypic; Antigens; Apoptosis; Autoantibodies; Cardiovascular Disease | 2012 |
Homocysteine-betaine interactions in a murine model of 5,10-methylenetetrahydrofolate reductase deficiency.
Topics: Animals; Betaine; Cardiovascular Diseases; Choline; Dose-Response Relationship, Drug; Female; Genoty | 2003 |
Targeting C-reactive protein for the treatment of cardiovascular disease.
Topics: Animals; C-Reactive Protein; Cardiovascular Diseases; Complement System Proteins; Drug Design; Hexan | 2006 |
Chemical knockout of C-reactive protein in cardiovascular disease.
Topics: Animals; C-Reactive Protein; Cardiovascular Diseases; Choline; Hexanes; Humans; Molecular Structure; | 2006 |
Clinical and angiographic results of percutaneous coronary revascularization using a trilayer stainless steel-tantalum-stainless steel phosphorylcholine-coated stent: the TriMaxx trial.
Topics: Aged; Angioplasty, Balloon, Coronary; Brazil; Cardiovascular Agents; Cardiovascular Diseases; Corona | 2007 |